Cartesian Therapeutics Inc
NASDAQ:RNAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Huaneng Lancang River Hydropower Inc
SSE:600025
|
CN |
|
Medios AG
XETRA:ILM1
|
DE |
|
Altamir SCA
PAR:LTA
|
FR |
|
Peria Karamalai Tea and Produce Company Ltd
NSE:PKTEA
|
IN |
|
S
|
Shanghai Yaoji Technology Co Ltd
SZSE:002605
|
CN |
|
Z
|
Zig Sheng Industrial Co Ltd
TWSE:1455
|
TW |
|
Blacksky Technology Inc
NYSE:BKSY
|
US |
|
SDI Ltd
ASX:SDI
|
AU |
|
A
|
AWC Bhd
KLSE:AWC
|
MY |
|
M
|
M4B SA
WSE:M4B
|
PL |
|
Tyson Foods Inc
NYSE:TSN
|
US |
|
Trex Company Inc
NYSE:TREX
|
US |
|
Tinybeans Group Ltd
ASX:TNY
|
AU |
|
Havilah Resources Ltd
ASX:HAV
|
AU |
|
Alice Queen Ltd
ASX:AQX
|
AU |
|
E
|
Ensari Deri Gida Sanayi ve Ticaret AS
IST:ENSRI.E
|
TR |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Cartesian Therapeutics Inc
NASDAQ:RNAC
|
162.8m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Cartesian Therapeutics Inc
Glance View
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cartesian Therapeutics Inc is -4 658.6%, which is below its 3-year median of -1 055.8%.
Over the last 3 years, Cartesian Therapeutics Inc’s Net Margin has decreased from 31.9% to -4 658.6%. During this period, it reached a low of -4 658.6% on Jan 1, 2026 and a high of 31.9% on Dec 31, 2022.
